| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Scientific Officer
1 company
Carter Todd Alfred serves as a Chief Scientific Officer at VYGR. Across recent SEC filings that breaks down to 0 buys and 18 sells. Those positions are worth an estimated $548K at current prices.
Historically, Carter Todd Alfred's trades have earned a middling insider score of 68/100 across 16 rated trades. Over a 12-month horizon, 78.6% of those trades were profitable, with an average 12-month return of +15.7%.
The biggest single holding is VYGR (~$548K) as Chief Scientific Officer. The recent filings there lean toward selling, a net 52,364 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2023 | VYGR Voyager Therapeutics, Inc. | Chief Scientific Officer | Sale+OE10b5-1 | 5,000 | $11.41 | $57,050.00 | -7.1% | -32.6% | -30.9% | |
| Mar 20, 2023 | VYGR Voyager Therapeutics, Inc. | Chief Scientific Officer | Sell | 2,193 | $7.76 | $17,017.68 | -3.2% | +81.0% | +30.1% | |
| Feb 17, 2023 | VYGR Voyager Therapeutics, Inc. | Chief Scientific Officer | Sell | 738 | $7.45 | $5,498.10 | -1.1% | +65.1% | +1.6% | |
| Feb 13, 2023 | VYGR Voyager Therapeutics, Inc. | Chief Scientific Officer | Sell | 797 | $7.67 | $6,112.99 | -2.3% | +33.2% | -8.5% | |
| Jan 17, 2023 | VYGR Voyager Therapeutics, Inc. | Chief Scientific Officer | Sell | 1,106 | $9.85 | $10,892.42 | -3.1% | -14.0% | -20.7% | |
| Jan 6, 2023 | VYGR Voyager Therapeutics, Inc. | Chief Scientific Officer | Sell | 388 | $6.41 | $2,487.08 | -1.1% | +14.8% | +27.2% |